Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Trial Identifier:	D419MC00006
Sponsor:	AstraZeneca
Start Date:	June 2023
Primary Completion Date:	April 2025
Study Completion Date:	April 2025
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Nara, Japan
Japan	Wakayama, Japan
Japan	Yamaguchi, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.